BMC Immunology is a prominent open-access journal published by BMC that has been at the forefront of immunological research since its inception in 2000. Based in the United Kingdom, this journal aims to advance the understanding of immune system functions and disorders through high-quality, peer-reviewed articles. With an impressive scope encompassing various facets of immunology, BMC Immunology has earned a Q3 ranking in the Immunology category according to the 2023 category quartiles, demonstrating its growing impact and relevance in the scientific community. Researchers and professionals will find valuable insights in its array of published works, spanning both foundational studies and innovative applications. The journal's commitment to open access ensures that cutting-edge research is freely available, fostering collaboration and advancement in the field. For those looking to stay updated on the latest developments in immunology, BMC Immunology stands as an essential resource for researchers, professionals, and students alike.

MOLECULAR IMMUNOLOGY, published by Pergamon-Elsevier Science Ltd in the United Kingdom, is a highly regarded journal in the fields of Immunology and Molecular Biology. With a focus on advancing the understanding of the immune system at the molecular level, the journal has been a critical resource since its inception in 1975. The journal is currently listed in the second quartile (Q2) of its category as per the 2023 rankings, indicating its substantial impact in both Immunology and Molecular Biology research. Researchers and professionals benefit from the journal's rigorous peer-review process and its commitment to publishing high-quality original research, reviews, and methodological studies that explore the intricate dynamics of immune responses. Although it does not currently offer an open access option, MOLECULAR IMMUNOLOGY remains an essential platform for scholars, emphasizing the significance of molecular interactions within the immune system and their implications in health and disease.

Clinical and Experimental Immunology, published by Oxford University Press, is a premier journal that has been a cornerstone in the field of immunology since its inception in 1966. With an ISSN of 0009-9104 and an E-ISSN of 1365-2249, this journal holds a significant position in academic research, currently ranking in the Q2 category for both Immunology and Allergy (2023). Its impactful contributions are reflected in its Scopus rankings, where it stands at Rank #63 out of 233 in Immunology and Allergy, placing it in the 73rd percentile, and Rank #73 out of 236 in Immunology and Microbiology. Researchers, healthcare professionals, and students will find this journal an invaluable resource for cutting-edge studies, reviews, and clinical advancements in the ever-evolving domain of immunology. While the publication does not offer open-access options, it remains a pivotal platform for disseminating knowledge that impacts both clinical practice and experimental research.

INTERNATIONAL IMMUNOLOGY, published by OXFORD UNIV PRESS, stands out as a premier journal in the field of immunology, providing a vital platform for disseminating groundbreaking research and innovative developments within the discipline. With an impressive Q1 ranking in Immunology and Allergy, as well as in Medicine (miscellaneous), it consistently showcases high-impact studies that contribute to the advancement of immunological knowledge. The journal spans over three decades, from its inception in 1989 to its ongoing contributions as of 2024, thus solidifying its reputation in the scientific community. Researchers, professionals, and students will find valuable articles that delve into the complexities of immune responses, therapeutic interventions, and emerging immunological paradigms, ensuring INTERNATIONAL IMMUNOLOGY remains at the forefront of knowledge in the life sciences.

Immunity, Inflammation and Disease is a premier open-access journal published by WILEY, dedicated to advancing the field of immunology and allergy. Launched in 2013, this journal has established itself as a significant platform for researchers and professionals to disseminate high-quality research findings and innovative insights that address critical issues in immune responses and inflammatory diseases. With an impact factor that reflects its growing influence and a current ranking in Q3 for Immunology and Q2 for Immunology and Allergy, this journal serves a diverse audience keen on exploring cutting-edge developments. Researchers are encouraged to submit their work to share their findings with a global reach, foster collaboration, and enhance the understanding of immune mechanisms and therapeutic strategies. Accessible since its inception, Immunity, Inflammation and Disease is committed to open science, ensuring that vital research is freely available for the advancement of knowledge within the academic community and beyond.

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, published by Mary Ann Liebert, Inc, stands out as a pivotal resource in the fields of immunology, virology, and cell biology, providing comprehensive insights into cytokine functions and their roles in immune responses. With ISSN 1079-9907 and E-ISSN 1557-7465, the journal aims to disseminate innovative research that advances our understanding of interferon and cytokine biology, a crucial aspect for developing therapeutic strategies against various diseases. Covering a broad scope of research from 1995 to 2024, it boasts a respectable impact factor within its category quartiles, ranking Q2 in Medicine (miscellaneous) and Q3 in the domains of Cell Biology, Immunology, and Virology as of 2023. While it does not provide open access options, the journal remains essential for academics, researchers, and professionals dedicated to exploring the complexities of immune signaling pathways and their implications for health and disease. The journal’s consistent contribution to scientific discourse underscores its importance in elevating query-driven studies to foster advancements in biomedical science.

Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.

Seminars in Immunopathology is a premier academic journal published by SPRINGER HEIDELBERG, focusing on the intricate relationships between immune responses and pathologies. With an ISSN of 1863-2297 and an E-ISSN of 1863-2300, this journal delivers cutting-edge research and insights to its readers, contributing significantly to the fields of immunology and allergy, as reflected in its Q1 quartile ranking in both categories for 2023. Positioned in a highly competitive niche, it ranks #18 out of 233 in Immunology and Allergy and #22 out of 236 in Immunology and Microbiology, highlighting its impact within the scientific community. Seminars in Immunopathology publishes comprehensive reviews and research articles, aiming to advance understanding of immune mechanisms in disease and promote interdisciplinary collaboration. Accessible from Germany, this journal is a vital resource for researchers, clinicians, and students seeking to stay at the forefront of immunological advancements and therapeutic innovations.

IMMUNOBIOLOGY is a prestigious academic journal published by Elsevier GmbH that significantly contributes to the fields of hematology and immunology. With its ISSN 0171-2985 and E-ISSN 1878-3279, this journal has been disseminating impactful research since 1979, positioning itself at the forefront of immunological and hematological advances. The journal holds a commendable ranking of Q2 in Hematology and Q3 in both Immunology and Immunology and Allergy, indicating its relevance and influence within the scientific community, as reflected by its Scopus rankings. Although IMMUNOBIOLOGY operates under a subscription model, it remains dedicated to expanding knowledge across disciplines, fostering innovative research, and facilitating connections among researchers, professionals, and students. Situated in Munich, Germany, this journal is continually evolving and aims to remain an essential resource for the latest discoveries and insights in the realms of immunity and blood disorders, ultimately enhancing our understanding of complex biological systems.

ImmunoTargets and Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of immunology and its various therapeutic applications. Since its inception in 2012, the journal has rapidly become a vital resource for researchers, professionals, and students, achieving notable recognition with a Q1 ranking in both Immunology and Immunology and Allergy categories as of 2023. With an impressive Scopus ranking of #22 out of 233 in Medicine - Immunology and Allergy, and #25 out of 236 in Immunology and Microbiology, this journal maintains a 90th percentile standing in its field. ImmunoTargets and Therapy not only publishes original research articles, reviews, and clinical studies, but also fosters an inclusive platform for the dissemination of innovative findings critical to the fight against immunological disorders. Based in New Zealand, it serves a global audience, promoting knowledge exchange and collaboration through its open access model.